Back to top
more

Theravance Biopharma (TBPH)

(Delayed Data from NSDQ)

$8.94 USD

8.94
264,778

+0.19 (2.17%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $8.95 +0.01 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 250)

Industry: Medical - Drugs

Zacks News

CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y

CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates

Zoetis' (ZTS) earnings and revenues beat estimates for the fourth quarter of 2021.

Zacks.com featured highlights include Theravance Biopharma, PattersonUTI Energy and Select Energy Services

Theravance Biopharma, PattersonUTI Energy and Select Energy Services are included in this blog.

Tirthankar Chakraborty headshot

3 Best Stocks to Buy Right Away for Earnings Acceleration

Invest in Theravance Biopharma (TBPH), PattersonUTI Energy (PTEN) & Select Energy Services (WTTR) at the moment for superb earnings acceleration.

Catalyst's (CPRX) Stock Up on 2022 Guidance for Firdapse

Catalyst Pharmaceuticals (CPRX) reports preliminary sales figures for the fourth quarter. The company also provides its revenue guidance for 2022.

Lannett (LCI) Reports Q2 Loss, Misses Revenue Estimates

Lannett (LCI) delivered earnings and revenue surprises of -21.88% and 14.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Theravance Biopharma (TBPH) Stock Options

Investors need to pay close attention to Theravance Biopharma (TBPH) stock based on the movements in the options market lately.

Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance's (TBPH) Q3 Earnings Beat, Restructuring On Track

Theravance's (TBPH) loss narrows in the third quarter of 2021 while revenues decline year over year. Stock down.

Theravance Biopharma (TBPH) Reports Q3 Loss, Lags Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 20.00% and -2.64%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Theravance Biopharma (TBPH) Report Negative Earnings Next Week? What You Should Know

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Down 51.5% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win

AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.

Theravance (TBPH) to Cut Workforce, Hypotension Study Fails

Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic neurogenic orthostatic hypotension fails to meet goal. The company plans to cut its workforce by 75%. Stocks falls.

AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M

AzurRx BioPharma (AZRX) acquires First Wave Bio for $229 million. Following the acquisition, the company is set to rename itself as First Wave BioPharma.

Why Is Theravance Bio (TBPH) Down 36.5% Since Last Earnings Report?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: REGN, MRNA Offer COVID-19 Updates, TBPH Down on Study Update

Regulatory and pipeline updates from Regeneron (REGN) and Moderna (MRNA), among others have been in focus in the biotech industry over the past week.

Theravance (TBPH) Suffers 2nd Study Failure in Two Months

Theravance's (TBPH) mid-stage candidate, izencitinib, fails in a study evaluating it in patients with ulcerative colitis.

Bausch's (BHC) Q2 Earnings Beat Estimates, Revenues Miss

Bausch (BHC) beats on earnings but misses on sales in the second quarter. The company also lowers its annual revenue guidance.

Pacira's (PCRX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

Pacira's (PCRX) earnings and revenues in the second quarter of 2021 surpass estimates. Exparel sales surge year over year.

Theravance's (TBPH) Q2 Earnings Beat, Pipeline On Track

Theravance's (TBPH) loss narrows in the second quarter of 2021 while revenues decline year over year. Stock up.

Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 16.67% and -14.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Theravance (TBPH) COVID-19 Therapy Fails in Mid-Stage Study

Theravance's (TBPH) JAK inhibitor candidate, nezulcitinib, fails to achieve statistically significant improvement in the number of respiratory failure-free days in hospitalized COVID-19 patients with lung injury.

Theravance Bio (TBPH) Down 13% Since Last Earnings Report: Can It Rebound?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.